Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fat injections and lasers join forces to fight stubborn scars

NCT ID NCT07679217

Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study compares two treatments—nanofat injections and fractional CO2 laser—used alone or together for post-traumatic atrophic scars (depressed scars from injury). Sixty participants receive one of the three approaches. The goal is to see if combining both treatments improves scar appearance more than either alone, using skin exams and patient feedback.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Autologous nanofat injection and fractional CO2 laser
What this could lead to
If successful, combining nanofat with CO2 laser could offer a more effective, minimally invasive way to improve the appearance of traumatic scars.
What could go wrong
This is a small, early-stage study with no blinding, so results may not be conclusive. Individual results vary, and risks include infection or uneven healing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants aged 12 years or older. * Presence of post-traumatic atrophic scar(s) of at least 6 months' duration. * No scar treatment received during the previous 6 months. * Willingness and ability to provide written informed consent (or assent with -parental/guardian consent for minors, according to local regulations). * Willingness to comply with study procedures and follow-up assessments. Exclusion Criteria: * Hemoglobin \<10 g/dL. * Active infection or viral skin disease. * Coagulopathy or hemophilia. * Current anticoagulant therapy. * Diabetes mellitus. * History of keloid formation. * History of malignancy or prior radiation therapy. * Immunosuppression. * Long-term systemic corticosteroid therapy. * Photosensitivity disorders. * Pregnancy or breastfeeding. * Renal or hepatic disease. * Systemic diseases affecting wound healing. * Thin patients with insufficient adipose tissue for adipose tissue harvesting. * Previous scar treatment within the preceding 6 months. * Use of systemic retinoids within the preceding 6 months. -Use of topical retinoids within the preceding 2 weeks.-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrophic scar are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

severe cutaneous adverse reaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrophic scar Post-traumatic atrophic scar Scar

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tanta University Hospital

    Tanta, Gharbia Governorate, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.